Enzon Pharmaceuticals Executes 100-for-1 Reverse Stock Split, Trades Under ENZND
Enzon Pharmaceuticals implemented a 100-for-1 reverse stock split effective March 24, 2026, with its shares trading under the temporary symbol ENZND for 20 trading days to consolidate outstanding shares. The company aims to boost marketability and align its share price with investor expectations through this consolidation.
1. Reverse Stock Split Implementation
Enzon Pharmaceuticals implemented a 100-for-1 reverse stock split that became effective at 4:30 pm ET on March 24, 2026. Following the split, each 100 pre-split shares converted into one post-split share, and the stock will trade under the temporary symbol ENZND for 20 trading days on the OTCQB market.
2. Fractional Shares and Cash Payments
No fractional shares will be issued; stockholders entitled to fractions will receive a proportional cash payment in lieu of fractional interests. This approach ensures uniform shareholding and simplifies the administrative process post-split.
3. Rationale and Market Positioning
The company pursued the reverse split to consolidate its outstanding shares, boost per-share pricing, and improve appeal to institutional and retail investors. Aligning its share price with market expectations may enhance compliance and broaden potential investor interest.
4. Market Capitalization and Trading Metrics
Following the split, Enzon’s market capitalization stands around $4.45 million, based on the reduced share count. Trading volume on the announcement day reached approximately 207,734 shares, reflecting investor attention to the corporate action.